MedTrace Logo

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

NCT05104359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 825

Last updated 2022-07-27

No results posted yet for this study

Summary

This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig spike antibody measurements). Rates of antibody level decay after vaccination will be assessed. The efficacy of using antibody levels to help guide the timing of booster doses among HIV-negative and HIV-positive patients will be evaluated.

Conditions

  • COVID-19
  • COVID-19 Vaccines
  • Immunogenicity, Vaccine

Interventions

OTHER

Observational

HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.

Sponsors & Collaborators

  • AIDS Healthcare Foundation

    collaborator OTHER

  • Epividian

    lead INDUSTRY

Principal Investigators

  • Ricky Hsu, MD · AHF Midtown Manhattan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104359 on ClinicalTrials.gov